Kernal Bio Secures Investment to Advance Cancer Cell Therapy, Expands Leadership Team

0
11
Yusuf Erkul, M.D., M.B.A.

BOSTON–Kernal Bio has secured a strategic investment from the Institute for Follicular Lymphoma Innovation (IFLI) to accelerate development of its experimental CAR-T cell therapy, KR-402, while announcing several senior leadership and board appointments.

The Boston biotechnology company is developing KR-402 as a potential treatment for B-cell cancers, including follicular lymphoma, as well as autoimmune diseases such as multiple sclerosis.

The investment amount was not disclosed. The funding builds on Kernal Bio’s previously announced award of up to $48 million from the Advanced Research Projects Agency for Health (ARPA-H), which supports development of the company’s next-generation CAR-T technology.

Kernal Bio also receives support from NVIDIA, Microsoft, and Eli Lilly through the Lilly Gateway Labs accelerator.

“We’re honored to partner with IFLI to advance KR‑402 toward the clinic,” said Yusuf Erkul, M.D., M.B.A., Co-Founder and Chief Executive Officer of Kernal Bio. “This partnership brings together organizations with a shared commitment to developing new treatment options for people living with follicular lymphoma, and to ultimately finding a cure.”

KR-402 is being developed using Kernal Bio’s proprietary mRNA 2.0 platform, which combines artificial intelligence-designed messenger RNA with targeted lipid nanoparticles to program immune cells directly inside the body.

Traditional CAR-T therapies generally require immune cells to be collected from patients, genetically modified in specialized manufacturing facilities, and then infused back into the bloodstream.

Kernal Bio’s approach is designed to generate CAR-T cells directly within the patient, potentially reducing manufacturing complexity, treatment delays, and costs.

The platform uses cell-selective mRNA molecules developed from multi-omics data and antibody-coated lipid nanoparticles to deliver genetic instructions to targeted immune cells.

“With support from IFLI, ARPA-H, and our ecosystem of partners, we are accelerating the transformation of CAR‑T therapy to an in vivo approach that could improve the patient journey and expand patient access for serious diseases,” said Manfred Kraus, Ph.D., Senior Vice President of R&D Therapeutics at Kernal Bio.

IFLI, an organization focused on advancing treatments for follicular lymphoma, said the investment reflects the potential of Kernal Bio’s technology to address limitations associated with conventional cell therapies.

“IFLI is proud to support the development of KR-402 as part of our commitment to catalyzing next-generation treatments for follicular lymphoma,” said David McCullagh, Managing Director of IFLI. “Based on compelling preclinical data, Kernal Bio’s in vivo CAR-T platform has the potential to address important limitations of current approaches, including lengthy manufacturing timelines and treatment complexity, and ultimately broaden access to transformative immunotherapies for the follicular lymphoma.”

Alongside the investment, Kernal Bio announced the appointment of Kirsten Kester, M.B.A., as Chief Business Officer and Sieun K. Barnes, Ph.D., as Director of Process Development (CMC).

Kester joins the company from Obsidian Therapeutics, where she served as Senior Vice President and helped oversee corporate strategy, financing activities, and strategic partnerships.

During her tenure at Obsidian, she participated in a $350 million private placement associated with the company’s public listing through a reverse merger with Galera Therapeutics, as well as its Series B and Series C financing rounds.

She also managed Obsidian’s collaboration with Bristol Myers Squibb and helped negotiate a strategic partnership with Vertex Pharmaceuticals.

Earlier in her career, Kester worked in life sciences consulting at the Frankel Group and Huron, now part of Oliver Wyman.

She holds a bachelor’s degree from Harvard College and an M.B.A. from Harvard Business School.

Barnes joins Kernal Bio from Moderna, where she most recently served as Associate Director of Process Development and Analytical Program Lead.

At Moderna, she worked on lipid nanoparticle formulations and analytical strategies supporting mRNA programs from early development through late-stage manufacturing.

Her responsibilities included developing analytical control strategies, supporting regulatory submissions, and incorporating AI-enabled analytics into manufacturing processes.

Before Moderna, Barnes worked in process engineering at Vertex Pharmaceuticals.

She earned her Ph.D. from Case Western Reserve University and completed postdoctoral research at the Massachusetts Institute of Technology.

Kernal Bio also expanded its Board of Directors with the appointment of Stuart Chaffee, Ph.D., Chief Executive Officer of Forward Therapeutics.

Chaffee has held senior leadership and founding roles at several biotechnology companies, including Affinivax, Praxis Precision Medicines, Kymera Therapeutics, and QuantX.

Carol O’Hear, M.D., Ph.D., Chief Medical Officer of Exelixis, joined the board as an observer.

O’Hear previously served as Vice President of Oncology Clinical Development at Gilead and held senior oncology and hematology development positions at Genentech.

Patrick Lundgren, Ph.D., also joined as a board observer. Lundgren focuses on biotechnology investments and company formation at Hummingbird Ventures and previously worked at Flagship Pioneering.

The company further expanded its Advisory Board with five appointments spanning immunology, neurology, biotechnology, and corporate development.

The new advisers include William H. Robinson, M.D., Ph.D., James Raitt Professor and Chief of the Division of Immunology and Rheumatology at Stanford University, and Thomas Dörner, M.D., Professor of Rheumatology at Charité University Hospitals in Berlin.

Lawrence Steinman, M.D., Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford University, also joined the board. Steinman is a member of the National Academy of Sciences and the National Academy of Medicine.

Bruce Peacock, a biotechnology executive and investor with experience at several pharmaceutical companies, was also appointed. He previously held senior positions at Ophthotech/Iveric Bio, Eye Bio, Centocor, and Cephalon and founded Interius BioTherapeutics.

Peacock currently serves as an Operating Partner at Agent Capital and a Venture Partner at SV Life Sciences.

The fifth appointee is Craig Gibbs, Ph.D., Chief Executive Officer of Vivace Therapeutics and former Chief Executive Officer of Asher Bio and Chief Business Officer of Forty Seven, which was acquired by Gilead.

Kernal Bio said the additional leadership and advisory expertise will support the advancement of KR-402 through preclinical development and toward potential human clinical testing.

The experimental therapy remains in preclinical development, and its safety and effectiveness in humans have not yet been established.

Leave A Reply

Please enter your comment!
Please enter your name here